The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.

@article{Gurbel2010TheEO,
  title={The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients.},
  author={Paul A Gurbel and Kevin P. Bliden and Mark J. Antonino and Gillian Stephens and Daniel D. Gretler and Marta Jurek and Ruth E Pakyz and Alan R. Shuldiner and Pamela B Conley and Udaya S. Tantry},
  journal={Journal of thrombosis and haemostasis : JTH},
  year={2010},
  volume={8 1},
  pages={43-53}
}
UNLABELLED To study the effect of a new direct acting reversible P2Y(12) inhibitor, elinogrel (PRT060128), and the relation to cytochrome P450 (CYP) polymorphisms in patients with high platelet reactivity (HPR) on standard dual antiplatelet therapy. METHODS AND RESULTS We studied the pharmacodynamic and pharmacokinetic effects of a single 60-mg oral dose of elinogrel in 20 of 45 previously stented stable patients with HPR. We also genotyped for CYP2C19*2,3,5,17 and CYP3A5*3. Platelet… CONTINUE READING
33 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Prognostic significance of post-clopidogrel platelet reactivity assessed by a pointof-care assay on thrombotic events after drug-eluting stent implantation

  • PriceMJ, S Endemann, +7 authors PS. Teirstein
  • Eur Heart J
  • 2008

Similar Papers

Loading similar papers…